e-ISSN: Pending
Negative / Null Result ReportOpen accessMedicine· cited by 14

Emerging biologic frontiers for Sjogren’s syndrome: Unveiling novel approaches with emphasis on extra glandular pathology

Xiao Li; Maierhaba Maitiyaer; Qing Tan; Wen Hui Huang; Yü Liu; Zhi Ping Liu; Yue Qiang Wen; Yu Zheng · 2024 · Frontiers in Pharmacology

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

Primary Sjögren's Syndrome (pSS) is a complex autoimmune disorder characterized by exocrine gland dysfunction, leading to dry eyes and mouth. Despite growing interest in biologic therapies for pSS, FDA approval has proven challenging due to trial complications. This review addresses the absence of a molecular-target-based approach to biologic therapy development and highlights novel research on drug targets and clinical trials. A literature search identified potential pSS treatment targets and recent advances in molecular understanding. Overlooking extraglandular symptoms like fatigue and depr

Abstract by Xiao Li; Maierhaba Maitiyaer; Qing Tan; Wen Hui Huang; Yü Liu; Zhi Ping Liu; Yue Qiang Wen; Yu Zheng, Frontiers in Pharmacology (2024) — licensed CC BY 4.0.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: OpenAlex · DOI 10.3389/fphar.2024.1377055